Moderna Inc. is experiencing a significant uptick in its stock price, fueled by promising developments in its cancer treatment pipeline.
Moderna Inc. (NASDAQ:MRNA) is rising today, gaining 4.61% to close at CA$198.76. This positive movement follows a series of encouraging developments regarding its mRNA-based cancer treatments, particularly its collaboration with Merck.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$75.43B
52W high
$208.90
52W low
$22.28
1W change
-3.02%
Beta
1.11
Analyst Price Targets
Based on 27 analysts covering MRNA · as of Oct 2, 2026
Wall Street analysts forecast MRNA stock price to fall 36.1% over the next 12 months.
Consensus
Hold3.22 / 5.00
Avg. Target
C$120.67
-36.1% Upside
Previously C$119.56 on Sep 17, 2026
Current Price
C$188.94
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
116.3%
Annualized
90-Day Vol
210.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$225.88
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$200.53 | C$134.24 – C$299.55 |
| 60 trading days | C$212.83 | C$120.65 – C$375.41 |
| 90 trading days | C$225.88 | C$112.72 – C$452.64 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are optimistic about Moderna's future growth potential, especially in oncology, as the company continues to advance its innovative therapies.
4.61% Increase in Stock Price
Moderna's stock has gained 4.61% today, reflecting strong investor confidence in its oncology pipeline and upcoming market events.
Bull case
The recent surge in Moderna's stock is mainly due to successful clinical trial results for its combined therapy candidate for melanoma. This progress has opened up significant revenue growth opportunities. Additionally, the company is set to be included in the Nasdaq-100 index, which is likely to attract more institutional investment.
Bear case
Despite the positive momentum, some analysts warn that Moderna's valuation might be too high and not fully supported by its current revenue. There are concerns about whether its growth can be sustained and the potential for disappointing results in future trials.
Positive Clinical Trial Results
Advertisement
Moderna's recent success in clinical trials for its melanoma treatment, developed in partnership with Merck, has greatly improved investor sentiment. The therapy has shown promising results in enhancing recurrence-free survival rates, which is crucial for its market potential.
Upcoming Nasdaq-100 Inclusion
Moderna is set to join the Nasdaq-100 index on October 9, which is expected to boost its visibility and appeal to institutional investors. This inclusion is likely to increase demand for the stock, especially as funds adjust their portfolios.
Market Outlook and Analyst Sentiment
While many investors are optimistic about Moderna's future, some analysts express caution regarding its high valuation compared to its current earnings. The company's ability to keep up its momentum after recent gains will be closely watched as it faces upcoming clinical trials and market changes.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
